

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
52676	19/NE/0250	265193	A Phase 1B, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL	Number Agreed	3	3	Date Agreed	20/10/2020	1	20/10/2020	1	Recruitment Finished	
52677	19/EM/0047	257111	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA)	Number Agreed	4	4	Date Agreed	31/07/2020	4	07/11/2020	4	Recruitment Finished	
52679	19/NW/0363	250571	Protocol I4V-MC-JAJA (RA-BRIDGE) Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis	Range Agreed	1	2	Date Agreed	01/02/2026	2	09/11/2020	2	Recruitment Finished	
52680	18/NW/0004	239074	A randomised, double-blind, placebo-controlled, single, multiple ascending dose trial to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis	Number Agreed	4	4	Date Agreed	13/09/2019	4	07/12/2020	4	Recruitment Finished	
52681	19/SC/0309	264959	A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis	Range Agreed	1	2	Date Agreed	02/12/2020	2	02/12/2020	2	Recruitment Finished	